GRAFTYS announces the extension of its CE mark for its calcium phosphate cements to now include GRAFTYS® HBS and GRAFTYS® Quickset for the indication of subchondral bone marrow lesions around the knee joint (BML)

Aix-en-Provence, September 14th, 2015 – GRAFTYS SA, a company focused on development and commercialization of orthopedic biomaterials, is pleased to announce that it has obtained authorization from its notified body, NSAI (National Standards Authority of Ireland) for European commercialization for two of its cements (GRAFTYS® HBS and GRAFTYS® Quickset) for treatment of bone marrow lesions caused by traumatic injury. GRAFTYS® HBS and GRAFTYS® Quickset are highly injectable and resorbable calcium phosphate cements, developed by GRAFTYS and currently commercialized in 23 countries. Subchondral bone marrow lesions, also known as bone marrow edema, results in loss of bone volume and micro fractures and loss of mechanical strength of the subchondral bone above or below the knee joint, which may cause an inflammatory reaction and damage the articular cartilage.